Welcome to our dedicated page for Silence Therapeutics Plc SEC filings (Ticker: SLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silence Therapeutics plc (Nasdaq: SLN) SEC filings page brings together the company’s regulatory disclosures as a global clinical-stage biotechnology issuer. Through documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, Silence provides detailed information on its siRNA-based pipeline, financial condition and governance.
In its filings and furnished press releases, the company discusses the development of divesiran, a first-in-class siRNA candidate for polycythemia vera (PV), including Phase 1 and Phase 2 SANRECO study design, clinical data highlights and regulatory designations such as U.S. FDA Fast Track and Orphan Drug status for PV. Filings also reference other programs from the mRNAi GOLD™ platform, including zerlasiran (SLN360) for cardiovascular disease, SLN312 licensed to AstraZeneca and SLN548 for complement-mediated diseases, as well as early extra-hepatic siRNA targeting efforts.
Silence’s periodic reports provide quantitative data on research and development expenses, general and administrative costs, net losses, cash and short-term investment balances and contract liabilities. Risk factor sections and management commentary outline uncertainties related to clinical development, regulatory approvals, collaborations, manufacturing and intellectual property.
Current reports on Form 8-K document material events such as quarterly and annual financial results, completion of clinical trial enrollment milestones, leadership and Board changes, director resignations, and outcomes of shareholder votes at the annual general meeting. These filings also confirm that the company’s American Depositary Shares, each representing three ordinary shares, are listed on The Nasdaq Stock Market LLC under the symbol SLN.
On Stock Titan, SEC filings for SLN are updated in near real time from EDGAR, and AI-powered summaries help explain the key points in lengthy documents. Users can quickly scan 10-K and 10-Q reports, review 8-K event disclosures and track how Silence Therapeutics’ siRNA programs, financial profile and governance structure evolve over time.
Silence Therapeutics plc (SLN) – Form 4 insider activity: Director and 10% owner Richard Ian Griffiths, through Cream Capital Ltd., reported two open-market purchases of American Depositary Shares (ADS).
- 31 Jul 2025: 14,342 ADS at $6.18
- 1 Aug 2025: 4,034 ADS at $6.14
The combined 18,376 ADS cost roughly $113 k and lifted his indirect holding to 11,825,861 ADS. Each ADS converts into three ordinary shares and has no expiration date. Griffiths disclaims beneficial ownership beyond his pecuniary interest.
The transactions modestly increase an already large position (<0.02 % incremental) and do not affect control status, but fresh insider buying can be viewed as a mild vote of confidence. No sales, options, or other derivative moves were disclosed.
Silence Therapeutics plc (SLN) – Form 4 insider buying
10% owner Richard Ian Griffiths, via Cream Capital Ltd., disclosed open-market purchases on 21-22 Jul 2025 of 25,345 American Depositary Shares (ADS) at $6.04 and $6.09. Each ADS converts into three ordinary shares, increasing his indirect holding by roughly 76,035 ordinary shares.
Post-trade, Griffiths’ beneficial position totals ≈11.78 million ADS-equivalent shares. No sales were reported. Continued accumulation by a 10% holder generally signals confidence in the company’s outlook and may support sentiment toward SLN shares.
Silence Therapeutics (NASDAQ:SLN) filed a routine Form 8-K disclosing voting results from its 26 June 2025 Annual General Meeting. Shareholders approved all 13 resolutions, including the re-appointment of directors David Lemus, Tim McInerney, Iain Ross and Craig Tooman; an annual non-binding say-on-pay vote; ratification of PricewaterhouseCoopers LLP as both U.S. and U.K. auditors; adoption of the 2024 U.K. statutory accounts; and replacement of the company’s articles of association. Support levels exceeded 90% for most items (e.g., Craig Tooman re-elected with 78.23 M votes for vs. 28.4 k against). The board will continue to seek shareholder input on executive compensation annually. No other material business, strategic changes or financial disclosures were announced.
Silence Therapeutics Plc (SLN) – Schedule 13D/A Amendment No. 9
The filing discloses the updated beneficial ownership of long-time shareholder Richard Ian Griffiths and several Jersey-based entities he controls. After recent open-market activity and an increase in the company’s share capital, Mr. Griffiths now reports 34,543,302 ordinary shares (held directly and through seven entities), representing 24.4 % of SLN’s 141,690,849 outstanding shares. Voting and dispositive power for all shares is held solely by Mr. Griffiths.
Recent transactions: Between 8 May 2025 and 24 Jun 2025, Mr. Griffiths purchased an additional 543,581 ADSs on the open market for a combined cash consideration of US $2.7 million; each ADS equals three ordinary shares. These purchases were funded with personal or affiliated-company cash.
Entity breakdown:
- Ora Capital Ltd – 19,221,525 ordinary shares (13.6 %)
- Sarossa Plc – 1,815,522 shares
- Cream Capital Ltd – 3,967,896 shares
- Blake Holdings Ltd – 300,000 shares
- Ora Ventures Ltd – 360,000 shares
- Pinkey’s Ltd – 190,500 shares
- Direct holding – 8,687,859 shares
The amendment notes that the percentage ownership has changed because of both the incremental ADS purchases and dilution stemming from a recent increase in the Issuer’s share capital. No new contracts, voting agreements or other material relationships were reported, and a standard joint-filing agreement is included as an exhibit.
Silence Therapeutics plc (SLN) – Form 4 insider transaction. 10% owner Richard Ian Griffiths reported a series of open-market purchases of the company’s American Depositary Shares (ADSs) between 22 and 24 June 2025.
- Griffiths bought 20,977 ADS at $5.84 on 22 Jun, 35,005 ADS at $5.88 on 23 Jun and 26,624 ADS at $6.12 on 24 Jun, totalling 82,606 ADS.
- At the stated prices, the aggregate consideration is approximately US $0.49 million.
- Each ADS represents three ordinary shares; the purchases therefore add about 247,818 ordinary shares to the insider’s economic exposure.
- Following the transactions, Griffiths’ direct holding increased to 11,514,434 ADS, equivalent to roughly 34.5 million ordinary shares, consolidating his status as a 10%+ shareholder.
- All transactions are coded “P” (open-market buy) and were made directly, with no derivative features other than the standard ADS-to-ordinary-share convertibility.
Insider buying by a large, long-term holder is typically interpreted as a positive sentiment signal, suggesting management or significant shareholders view current valuation as attractive. However, the dollar amount, while meaningful, is modest relative to the insider’s existing position, limiting immediate balance-sheet impact.